 |
|
Researchers identify cancer-causing gene in many colon cancers
September 15, 2008BOSTON--Demonstrating that despite the large number of cancer-causing genes already identified, many more remain to be found, scientists at Dana-Farber Cancer Institute have linked a previously unsuspected gene, CDK8, to colon cancer.
The discovery of CDK8's role in cancer was made possible by new tools for assessing the activity of specific genes, say the authors of the new study. As these tools are further improved, the stream of newly discovered cancer genes is expected to increase, providing new avenues for therapy, the authors suggest. The findings are being published as an advanced online publication by the journal Nature on Sept. 14.
"This study provides confirmation that many of the genes involved in cancer have yet to be identified," remarked the study's senior author, William Hahn, MD, PhD, of Dana-Farber and the Broad Institute of Harvard and M.I.T. "When it comes to identifying gene targets for therapy, we've really only scratched the surface."
The study is noteworthy in another respect, as well, the authors indicated. Many of the abnormal proteins linked to cancer are known as "transcription factors" because they're able to "read" cell DNA and use that information for producing other cell proteins. Although transcription factors are important regulators, this class of proteins has proven to be impossible to target with drugs. Genes that influence such transcription factors, however, make attractive targets for drugs, since they can potentially disrupt the cancer process and disable tumor cells. CDK8 is such a gene.
The new study began with a focus on a protein called beta-catenin, a transcription factor that is overactive in nearly all colorectal cancers. Although overactive beta-catenin plays a role in the initial formation of tumors, other genetic abnormalities must occur for tumors to become fully malignant.
To determine which genes control the production of beta-catenin and are involved in the proliferation of colon cancer cells, the research team ran three screening tests. In the first two, they used RNA interference to shut down more than a thousand genes one by one and recorded the instances where beta-catenin activity decreased and the cells stopped growing. They then analyzed colon cancers for genes that had extra copies. When they examined where the results of the three tests overlapped, one gene stood out -- CDK8, explained Hahn, who is also an associate professor of medicine at Harvard Medical School
The protein produced from CDK8 is part of the "mediator complex," a conglomeration of proteins that serves as a bridge for compounds involved in gene transcription. "This study demonstrates that blocking CDK8 interferes with the proliferation of colon cancer cells that have high levels of the CDK8 protein and overactive beta-catenin," Hahn said. "Drugs that target CDK8 may be very useful against tumors whose growth is driven by beta-catenin."
Dana-Farber Cancer Institute
The study is noteworthy in another respect, as well, the authors indicated. Many of the abnormal proteins linked to cancer are known as "transcription factors" because they're able to "read" cell DNA and use that information for producing other cell proteins. Although transcription factors are important regulators, this class of proteins has proven to be impossible to target with drugs. Genes that influence such transcription factors, however, make attractive targets for drugs, since they can potentially disrupt the cancer process and disable tumor cells. CDK8 is such a gene.
The new study began with a focus on a protein called beta-catenin, a transcription factor that is overactive in nearly all colorectal cancers. Although overactive beta-catenin plays a role in the initial formation of tumors, other genetic abnormalities must occur for tumors to become fully malignant.
To determine which genes control the production of beta-catenin and are involved in the proliferation of colon cancer cells, the research team ran three screening tests. In the first two, they used RNA interference to shut down more than a thousand genes one by one and recorded the instances where beta-catenin activity decreased and the cells stopped growing. They then analyzed colon cancers for genes that had extra copies. When they examined where the results of the three tests overlapped, one gene stood out -- CDK8, explained Hahn, who is also an associate professor of medicine at Harvard Medical School
The protein produced from CDK8 is part of the "mediator complex," a conglomeration of proteins that serves as a bridge for compounds involved in gene transcription. "This study demonstrates that blocking CDK8 interferes with the proliferation of colon cancer cells that have high levels of the CDK8 protein and overactive beta-catenin," Hahn said. "Drugs that target CDK8 may be very useful against tumors whose growth is driven by beta-catenin."
Dana-Farber Cancer Institute
Beta-catenin Current Events and Beta-catenin News RSSWhat's the role of beta-catenin in colorectal cancers?
Beta-catenin, a central molecule of the Wnt-signaling pathway was previously known to involve in the tumorigenesis of various gastrointestinal cancers such as gastric cancer and colon cancer.
'Hub' of fear memory formation identified in brain cells
A protein required for the earliest steps in embryonic development also plays a key role in solidifying fear memories in the brains of adult animals, scientists have revealed. An apparent "hub" for changes in the connections between brain cells, beta-catenin could be a potential target for drugs to enhance or interfere with memory formation.
Analysis of alcoholics' brains suggests treatment target
An analysis of brain tissue samples from chronic alcoholics reveals changes that occur at the molecular level in alcohol abuse - and suggests a potential treatment target, according to researchers from Wake Forest University School of Medicine.
A gene for metastasis
Colorectal cancer is one of the most prevalent cancers in the Western world. The tumor starts off as a polyp but then turns into an invasive and violent cancer, which often spreads to the liver.
Enzyme eliminated by cancer cells holds promise for cancer treatment
An enzyme that cancer cells eliminate, apparently so they can keep proliferating, may hold clues to more targeted, effective cancer treatment, scientists say.
How does a zebrafish grow a new tail?
If a zebrafish loses a chunk of its tail fin, it'll grow back within a week. Like lizards, newts, and frogs, a zebrafish can replace surprisingly complex body parts. A tail fin, for example, has many different types of cells and is a very intricate structure. It is the fish version of an arm or leg.
Lost in the labyrinth
Blood cells have limited lifespans, which means that they must be continually replaced by calling up reserves, and turning these into the blood cell types needed by the body.
Omega-3 fatty acids inhibit growth of liver cancer cells
Two new studies by a University of Pittsburgh research team suggest that omega-3 fatty acids-substances that are found in high concentrations in fish oils and certain seeds and nuts-significantly inhibit the growth of liver cancer cells.
Researchers Reveal Possibility of Separating Anticancer Properties of Vitamin D
At the right dose, vitamin D is important for bone development and may help protect against the development of several cancers, particularly colorectal cancer.
Wnt signalling protein Dishevelled acts in the nucleus, not just in the cytoplasm
Researchers have identified that Dishevelled doesn't only function in the cytoplasm and at the cell membrane - it must also pass into the nucleus. A study published today in Journal of Biology reveals that Dishevelled, a key player in the Wnt/beta-catenin signalling pathway, has to be localised in the nucleus to perform a key aspect of its function. This discovery should shed light on both normal embryonic development and the development of cancer.
More Beta-catenin Current Events and Beta-catenin News Articles
| © 2008 BrightSurf.com |